Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adult stem cell therapies walk the line.

Literature DB >> 22871705

Adult stem cell therapies walk the line.

Laura DeFrancesco.

Abstract

Mesh：

Year: 2012 PMID： 22871705 DOI： 10.1038/nbt.2321

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

5 in total

Review 1. Regulating autologous adult stem cells: the FDA steps up.

Authors: Tamra Lysaght; Alastair V Campbell
Journal: Cell Stem Cell Date: 2011-11-04 Impact factor: 24.633

2. Texas legitimizes path around FDA oversight.

Authors: Laura DeFrancesco
Journal: Nat Biotechnol Date: 2012-05-07 Impact factor: 54.908

3. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial.

Authors: Richard J Powell; William A Marston; Scott A Berceli; Raul Guzman; Timothy D Henry; Amy T Longcore; Theresa P Stern; Sharon Watling; Ronnda L Bartel
Journal: Mol Ther Date: 2012-03-27 Impact factor: 11.454

Review 4. Human adipose stem cells: current clinical applications.

Authors: Phanette Gir; Georgette Oni; Spencer A Brown; Ali Mojallal; Rod J Rohrich
Journal: Plast Reconstr Surg Date: 2012-06 Impact factor: 4.730

Review 5. Concise review: bone marrow mononuclear cells for the treatment of ischemic syndromes: medicinal product or cell transplantation?

Authors: Natividad Cuende; Laura Rico; Concha Herrera
Journal: Stem Cells Transl Med Date: 2012-05-03 Impact factor: 6.940

5 in total

4 in total

Adult stem cell therapies walk the line.

Review 1. Regulating autologous adult stem cells: the FDA steps up.

2. Texas legitimizes path around FDA oversight.

3. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial.

Review 4. Human adipose stem cells: current clinical applications.

Review 5. Concise review: bone marrow mononuclear cells for the treatment of ischemic syndromes: medicinal product or cell transplantation?

1. Fresh from the biotech pipeline--2012.

2. When the best is the enemy of the good: the case of bone-marrow mononuclear cells to treat ischemic syndromes.

3. Advances in regenerative orthopedics.

Review 4. Managing the potential and pitfalls during clinical translation of emerging stem cell therapies.